{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:19:47Z","timestamp":1762917587677,"version":"3.37.3"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T00:00:00Z","timestamp":1430697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Key clinical message<\/jats:title><jats:p>The inflammation\u2010mediated comorbidities in myelofibrosis (<jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. <jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>1\u20102 inhibitors in <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>\u2010patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation\u2010mediated comorbidities.<\/jats:p>","DOI":"10.1002\/ccr3.281","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T14:39:19Z","timestamp":1430750359000},"page":"499-503","source":"Crossref","is-referenced-by-count":12,"title":["The impact of ruxolitinib treatment on inflammation\u2010mediated comorbidities in myelofibrosis and related neoplasms"],"prefix":"10.1002","volume":"3","author":[{"given":"Mads Emil","family":"Bj\u00f8rn","sequence":"first","affiliation":[{"name":"Department of Hematology Roskilde University Hospital Roskilde Denmark"},{"name":"Institute for Inflammation Research (IIR) Department of Infectious Diseases and Rheumatology Copenhagen University Hospital Rigshospitalet Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"Department of Hematology Roskilde University Hospital Roskilde Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,4]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-530865"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.35"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.876356"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-394775"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.020412"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28857"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348755"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031070"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.04.002"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12332"},{"key":"e_1_2_5_15_1","first-page":"172","article-title":"Studies on serum YKL\u201040 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer","volume":"53","author":"Johansen J. S.","year":"2006","journal-title":"Dan. Med. Bull."},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.01.004"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0736"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.009"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.764417"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01618.x"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.05.011"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112786"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.020"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-014-0227-0"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/283617"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12265"},{"key":"e_1_2_5_28_1","first-page":"233","article-title":"Promising new treatments for rheumatoid arthritis \u2010 the kinase inhibitors","volume":"69","author":"Yazici Y.","year":"2011","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.07.005"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.102"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4489"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.282"},{"key":"e_1_2_5_33_1","first-page":"95","article-title":"Ruxolitinib for the treatment of myelofibrosis: its clinical potential","volume":"8","author":"Ostojic A.","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V122.21.396.396","article-title":"Long\u2010term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3\u2010year update from COMFORT\u2010I","volume":"122","author":"Verstovsek S.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482232"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.092155"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02496-13"},{"key":"e_1_2_5_38_1","first-page":"394","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa R. A.","year":"2010","journal-title":"IDrugs"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23871"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2013.29"},{"key":"e_1_2_5_43_1","first-page":"2013","article-title":"Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis","volume":"32","author":"Grunwald M. R.","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_5_44_1","first-page":"73","article-title":"Combination therapy with interferon and JAK1\u20102 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F\u2010allele burden in polycythemia vera","volume":"3","author":"Bj\u00f8rn M. E.","year":"2014","journal-title":"Leuk. Res. Rep."}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccr3.281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccr3.281","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:27:01Z","timestamp":1696264021000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/ccr3.281"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.281","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"type":"print","value":"2050-0904"},{"type":"electronic","value":"2050-0904"}],"subject":[],"published":{"date-parts":[[2015,5,4]]}}}